Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2005 2
2006 2
2007 2
2008 1
2009 4
2010 2
2011 4
2013 5
2014 2
2015 4
2016 2
2017 5
2018 5
2019 6
2020 4
2021 6
2022 6
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
Treatment intensification following glucagon-like peptide-1 receptor agonist in type 2 diabetes: Comparative effectiveness analyses between free vs. fixed combination of GLP-1 RA and basal insulin. RESTORE-G real-world study.
Candido R, Nicolucci A, Larosa M, Rossi MC, Napoli R; RESTORE-G (Retrospective analysis on the therapeutic approaches after GLP-1 RA treatment in type 2 diabetes patients) Study Group. Candido R, et al. Nutr Metab Cardiovasc Dis. 2024 Mar 23:S0939-4753(24)00125-X. doi: 10.1016/j.numecd.2024.03.023. Online ahead of print. Nutr Metab Cardiovasc Dis. 2024. PMID: 38693036
Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal risk.
Fadini GP, Longato E, Morieri ML, Del Prato S, Avogaro A, Solini A; DARWIN-Renal Study Investigators. Fadini GP, et al. Lancet Reg Health Eur. 2024 Feb 1;38:100847. doi: 10.1016/j.lanepe.2024.100847. eCollection 2024 Mar. Lancet Reg Health Eur. 2024. PMID: 38328413 Free PMC article.
Treatment intensification following glucagon-like peptide-1 receptor agonist treatment in type 2 diabetes: The RESTORE-G real-world study.
Candido R, Nicolucci A, Larosa M, Rossi MC, Napoli R; RESTORE-G (Retrospective analysis on the therapeutic approaches after GLP-1 RA treatment in type 2 diabetes patients) Study Group. Candido R, et al. Nutr Metab Cardiovasc Dis. 2023 Nov;33(11):2294-2305. doi: 10.1016/j.numecd.2023.07.025. Epub 2023 Jul 22. Nutr Metab Cardiovasc Dis. 2023. PMID: 37679243 Free article.
Metabolic and clinical effect of alpha-lipoic acid administration in schizophrenic subjects stabilized with atypical antipsychotics: A 12-week, open-label, uncontrolled study.
Iannuzzo F, Basile GA, Campolo D, Genovese G, Pandolfo G, Giunta L, Ruggeri D, Di Benedetto A, Bruno A. Iannuzzo F, et al. Among authors: di benedetto a. Curr Res Pharmacol Drug Discov. 2022 Jun 28;3:100116. doi: 10.1016/j.crphar.2022.100116. eCollection 2022. Curr Res Pharmacol Drug Discov. 2022. PMID: 35992380 Free PMC article.
Comparative effectiveness and safety of glargine 300 U/mL versus degludec 100 U/mL in insulin-naïve patients with type 2 diabetes. A multicenter retrospective real-world study (RESTORE-2 NAIVE STUDY).
Fadini GP, Buzzetti R, Nicolucci A, Larosa M, Rossi MC, Cucinotta D; RESTORE-2 Study Group. Fadini GP, et al. Acta Diabetol. 2022 Oct;59(10):1317-1330. doi: 10.1007/s00592-022-01925-9. Epub 2022 Jul 21. Acta Diabetol. 2022. PMID: 35864262 Free PMC article.
57 results